178 related articles for article (PubMed ID: 30507300)
61. Urinary Metabolic Biomarkers in Cancer Patients: An Overview.
De Matteis S; Bonafè M; Giudetti AM
Methods Mol Biol; 2021; 2292():203-212. PubMed ID: 33651364
[TBL] [Abstract][Full Text] [Related]
62. Bladder cancer biomarkers: review and update.
Ghafouri-Fard S; Nekoohesh L; Motevaseli E
Asian Pac J Cancer Prev; 2014; 15(6):2395-403. PubMed ID: 24761840
[TBL] [Abstract][Full Text] [Related]
63. GC-MS based metabolomics used for the identification of cancer volatile organic compounds as biomarkers.
Lubes G; Goodarzi M
J Pharm Biomed Anal; 2018 Jan; 147():313-322. PubMed ID: 28750734
[TBL] [Abstract][Full Text] [Related]
64. A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.
Gebregiworgis T; Nielsen HH; Massilamany C; Gangaplara A; Reddy J; Illes Z; Powers R
J Proteome Res; 2016 Feb; 15(2):659-66. PubMed ID: 26759122
[TBL] [Abstract][Full Text] [Related]
65. Putative markers for the detection of early-stage bladder cancer selected by urine metabolomics.
Lin JY; Juo BR; Yeh YH; Fu SH; Chen YT; Chen CL; Wu KP
BMC Bioinformatics; 2021 Jun; 22(1):305. PubMed ID: 34090341
[TBL] [Abstract][Full Text] [Related]
66. MicroRNA-218 inhibits bladder cancer cell proliferation, migration, and invasion by targeting BMI-1.
Cheng Y; Yang X; Deng X; Zhang X; Li P; Tao J; Lu Q
Tumour Biol; 2015 Sep; 36(10):8015-23. PubMed ID: 25967457
[TBL] [Abstract][Full Text] [Related]
67. Metabolomics Approach to Male Lower Urinary Tract Symptoms: Identification of Possible Biomarkers and Potential Targets for New Treatments.
Mitsui T; Kira S; Ihara T; Sawada N; Nakagomi H; Miyamoto T; Shimura H; Yokomichi H; Takeda M
J Urol; 2018 May; 199(5):1312-1318. PubMed ID: 29175111
[TBL] [Abstract][Full Text] [Related]
68. Urinary metabolomics for discovering metabolic biomarkers of laryngeal cancer using UPLC-QTOF/MS.
Chen J; Hou H; Chen H; Luo Y; Zhang L; Zhang Y; Liu H; Zhang F; Liu Y; Wang A; Hu Q
J Pharm Biomed Anal; 2019 Apr; 167():83-89. PubMed ID: 30759408
[TBL] [Abstract][Full Text] [Related]
69. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy.
Hofner T; Macher-Goeppinger S; Klein C; Schillert A; Eisen C; Wagner S; Rigo-Watermeier T; Baccelli I; Vogel V; Trumpp A; Sprick MR
Urol Oncol; 2014 Jul; 32(5):678-86. PubMed ID: 24631171
[TBL] [Abstract][Full Text] [Related]
70. Metabolomic profiling of human lung tumor tissues - nucleotide metabolism as a candidate for therapeutic interventions and biomarkers.
Moreno P; Jiménez-Jiménez C; Garrido-Rodríguez M; Calderón-Santiago M; Molina S; Lara-Chica M; Priego-Capote F; Salvatierra Á; Muñoz E; Calzado MA
Mol Oncol; 2018 Oct; 12(10):1778-1796. PubMed ID: 30099851
[TBL] [Abstract][Full Text] [Related]
71. Applications of Metabolomics in Cancer Studies.
Armitage EG; Ciborowski M
Adv Exp Med Biol; 2017; 965():209-234. PubMed ID: 28132182
[TBL] [Abstract][Full Text] [Related]
72. Improving diagnosis of genitourinary cancers: Biomarker discovery strategies through mass spectrometry-based metabolomics.
Manzi M; Riquelme G; Zabalegui N; Monge ME
J Pharm Biomed Anal; 2020 Jan; 178():112905. PubMed ID: 31707200
[TBL] [Abstract][Full Text] [Related]
73. Metabolomic Analysis Using Liquid Chromatography/Mass Spectrometry for Gastric Cancer.
Liang Q; Wang C; Li B
Appl Biochem Biotechnol; 2015 Aug; 176(8):2170-84. PubMed ID: 26088916
[TBL] [Abstract][Full Text] [Related]
74. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
[TBL] [Abstract][Full Text] [Related]
75. Proteometabolomics of bladder cancer: current and future prospects.
Bansal N; Gupta A; Sankhwar SN
Cancer Biomark; 2015; 15(4):339-48. PubMed ID: 25792474
[TBL] [Abstract][Full Text] [Related]
76. Salivary metabolomics for cancer detection.
Sugimoto M
Expert Rev Proteomics; 2020 Sep; 17(9):639-648. PubMed ID: 33140667
[No Abstract] [Full Text] [Related]
77. CYFRA21-1 levels could be a biomarker for bladder cancer: a meta-analysis.
Kuang LI; Song WJ; Qing HM; Yan S; Song FL
Genet Mol Res; 2015 Apr; 14(2):3921-31. PubMed ID: 25966163
[TBL] [Abstract][Full Text] [Related]
78. Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases.
Chen Z; Kim J
BMC Urol; 2016 Mar; 16():11. PubMed ID: 27000794
[TBL] [Abstract][Full Text] [Related]
79. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
80. Metabolomics Biomarkers for Breast Cancer.
Günther UL
Pathobiology; 2015 Sep; 82(3-4):153-65. PubMed ID: 26330356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
